南药转债

Search documents
南药转债盘中下跌2.04%报133.129元/张,成交额1425.92万元,转股溢价率28.64%
Jin Rong Jie· 2025-08-27 06:21
8月27日,南药转债盘中下跌2.04%报133.129元/张,成交额1425.92万元,转股溢价率28.64%。 根据最新一期财务数据,2025年1月-3月,南京医药实现营业收入142.469亿元,同比增加2.11%;归属 净利润1.774亿元,同比增加11.49%;扣非净利润1.696亿元,同比增加9.86%。 截至2025年3月,南京医药筹码集中度非常分散。十大股东持股合计占比60.82%,十大流通股东持股合 计占比61.12%。股东人数5.641万户,人均流通股2.31万股,人均持股金额11.19万元。 可转换债券简称可转债,是一种可以在特定时间、按特定条件转换为普通股票的特殊企业债券,兼具债 权和股权的特征。一般而言,持有人可按照发行时约定的价格将债券转换成公司的普通股票的债券。如 果债券持有人不想转换,则可以继续持有债券,直到偿还期满时收取本金和利息,或者在流通市场出售 变现。 资料显示,南京医药股份有限公司成立于1951年,1996年在上海证券交易所上市,是中国医药流通行业较 早上市公司,现已发展成为跨地区、网络型的集团化企业。2014年末,公司引入境外战略投资者,积极探索 混合所有制改革。国资控 ...
固定收益点评:可转债新券投资策略怎么看?
Guohai Securities· 2025-07-14 13:01
Group 1 - The report identifies a significant increase in the number of new convertible bonds listed recently, leading to heightened market attention towards new issuances [7][8] - Convertible bonds are categorized into four main types: white horse, value, small market cap, and balanced, each exhibiting distinct pricing characteristics and investment opportunities, necessitating differentiated strategies for new issuances [7][26] Group 2 - White horse convertible bonds are characterized by high initial valuations and a generally high conversion premium, indicating a low investment cost-effectiveness. The report advises against participating in new issuances or buying on the first day due to systemic valuation risks [7][12][26] - Value convertible bonds typically show low initial valuations, with some even trading below par. The report highlights that institutional demand can drive prices upward post-initial trading, suggesting active participation in new issuances and buying during sell-offs for optimal risk-reward ratios [13][17][26] Group 3 - Small market cap convertible bonds exhibit significant price volatility due to limited liquidity, often leading to extreme pricing deviations from fundamentals. The report recommends avoiding high-price chasing and waiting for a price correction after 4-6 months for potential value recovery opportunities [21][27] - Balanced convertible bonds present relatively rational pricing and moderate volatility, with the report suggesting participation in new issuances and buying during initial sell-offs to achieve stable returns within 1-2 months [25][27]
南京医药: 中信建投证券股份有限公司关于南京医药股份有限公司向不特定对象发行可转换公司债券2025年度第三次临时受托管理事务报告
Zheng Quan Zhi Xing· 2025-06-24 17:13
证券代码:600713.SH 证券简称:南京医药 债券代码:110098.SH 债券简称:南药转债 中信建投证券股份有限公司 关于 南京医药股份有限公司向不特定对象发行可转 换公司债券 2025 年度第三次临时受托管理事务 报告 债券受托管理人 二〇二五年六月 重要声明 本报告依据《公司债券发行与交易管理办法》(以下简称"《管理办法》") 《公司债券受托管理人执业行为准则》《南京医药股份有限公司 2024 年向不特 定对象发行可转换公司债券之受托管理协议》(以下简称"《受托管理协议》") 《南京医药股份有限公司向不特定对象发行可转换公司债券募集说明书》(以下 简称"《募集说明书》")及其它相关信息披露文件以及南京医药股份有限公司(以 下简称"南京医药"、"发行人"、"上市公司"、"公司")出具的相关说明文件和提 供的相关资料等,由受托管理人中信建投证券股份有限公司(以下简称"中信建 投证券"或"受托管理人")编制。中信建投证券编制本报告的内容及信息均来源 南京医药提供的资料或说明。 本报告不构成对投资者进行或不进行某项行为的推荐意见,投资者应对相关 事宜做出独立判断,而不应将本报告中的任何内容据以作为中信建投 ...
南京医药: 南京医药关于“南药转债”开始转股的公告
Zheng Quan Zhi Xing· 2025-06-24 17:13
Core Viewpoint - The announcement details the issuance and terms of the convertible bond "NanYao Convertible Bond" by Nanjing Pharmaceutical Co., Ltd, including its conversion price, issuance scale, and relevant procedures for bondholders [1][2][3]. Group 1: Issuance Overview - The convertible bond code is 110098 and the bond name is "NanYao Convertible Bond" [1]. - The total issuance amount is 1,081.49 million RMB, with each bond having a face value of 100 RMB [2]. - The bond has a term of 6 years, from December 25, 2024, to December 24, 2030 [2]. Group 2: Conversion Terms - The conversion price is set at 5.12 RMB per share [2][4]. - The conversion period starts from July 1, 2025, and ends on December 24, 2030 [2][3]. - The bond has a tiered interest rate structure, starting at 0.20% in the first year and increasing to 2.00% in the sixth year [2]. Group 3: Conversion Procedures - Bondholders can apply for conversion during the specified conversion period on trading days [3]. - The conversion process includes a mechanism for handling fractional shares and the calculation of the actual convertible bond quantity [3][4]. - Newly converted shares will have the same rights as existing shares [4]. Group 4: Adjustment of Conversion Price - The initial conversion price was set at 5.29 RMB per share, which has been adjusted to 5.12 RMB due to a cash dividend distribution [5][6]. - The conversion price can be adjusted based on various corporate actions, including stock dividends and cash dividends [6][8]. - The company has the right to propose downward adjustments to the conversion price if the stock price falls below certain thresholds [8][9]. Group 5: Redemption and Sale Rights - The company may redeem the unconverted bonds at 108% of the face value within five trading days after maturity [10]. - Bondholders have the right to sell back their bonds to the company if the stock price falls below 70% of the conversion price during the last two interest years [10][12]. - Additional sale rights are available if there are significant changes in the use of raised funds [12].
南京医药: 南京医药关于因实施权益分派调整可转债转股价格的公告
Zheng Quan Zhi Xing· 2025-06-24 16:50
债券代码:110098 债券简称:南药转债 证券代码:600713 证券简称:南京医药 编号:ls2025-091 南京医药股份有限公司 关于因实施权益分派调整可转债转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ? 调整前转股价格:5.29 元/股 ? 调整后转股价格:5.12 元/股 ? "南药转债"本次转股价格调整实施日期:2025 年 6 月 30 日 限公司向不特定对象发行可转换公司债券注册的批复》(证监许可【2024】1736 号), 核准南京医药股份有限公司(以下简称"公司")本次可转换公司债券(以下简称"可 转债")发行。公司向不特定对象发行可转债 10,814,910 张,每张面值为人民币 100 元,并于 2025 年 1 月 20 日在上海证券交易所上市交易(债券简称:南药转债,债券 代码:110098),初始转股价格为 5.29 元/股。 一、转股价格调整依据 公司股份回购专用证券账户持有股数)为基数分配利润,向全体股东每 10 股派发现金 红利 1.70 元(含税)。在 ...
南京医药: 南京医药2023年度第一期中期票据兑付公告
Zheng Quan Zhi Xing· 2025-06-12 08:18
Group 1 - The company, Nanjing Pharmaceutical Co., Ltd., has announced the issuance of its first medium-term note for 2023, with a total issuance amount of 100,000 million yuan [1] - The bond, named "23 Nanjing Pharmaceutical MTN001," has an interest rate of 3.1% and a maturity date set for June 20, 2025 [1] - The main underwriters for this bond issuance are Bank of Communications Co., Ltd. and Industrial Bank Co., Ltd. [1] Group 2 - The bond's interest and principal repayment will be managed by the China Interbank Market Clearing House Co., Ltd., which will transfer funds to bondholders on the specified payment date [1] - In case the payment date falls on a public holiday, the payment will be postponed accordingly [1] - The company and the clearing house will not be liable for any losses incurred due to delays in fund transfers if bondholders fail to notify changes in their payment account in a timely manner [1]
南京医药: 南京医药关于可转换公司债券2025年度跟踪评级结果的公告
Zheng Quan Zhi Xing· 2025-06-03 10:37
证券代码:600713 证券简称:南京医药 编号:ls2025-076 债券代码:110098 债券简称:南药转债 南京医药股份有限公司 关于可转换公司债券 2025 年度跟踪评级结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 公司前次主体信用等级为"AA+",评级展望为"稳定";"南药转债"前 次信用等级为"AA+";评级机构为中诚信,评级时间为 2024 年 12 月 4 日。 中诚信在对本公司经营状况、行业情况进行综合分析与评估的基础上,于 评委函字2025跟踪 0283 号),本次公司主体信用等级为"AA+",评级展望 维持"稳定";"南药转债"信用等级为"AA+"。评级结果较前次评级没有变 化。 公司于同日披露上述《南京医药股份有限公司 2025 年度跟踪评级报告》 (信 评委函字2025跟踪 0283 号)全文,详见上海证券交易所网站(http://www.sse. com.cn) 特此公告 南京医药股份有限公司董事会 ? 前次跟踪评级结果:主体信用等级为"AA+",评级展望为"稳定", ...